NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials
By Nikita Chaurasia  Date: 2020-08-03

NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures among critical patients of COVID-19. According to independent researchers, RLF-100 apparently blocks the multiplication of the SARS coronavirus in human lung cells as well as monocytes.

The first rapid clinical recuperation report was posted by doctors from Houston Methodist Hospital. It described the recovery of a 54-year-old man who contracted COVID-19 while being treated for rejection of a multiple lung transplant and was taken off the ventilator within four days of treatment.

Similar outcomes were observed in more than 15 cases treated under emergency use IND (Investigational New Drug), sources claimed. The FDA extended its access protocols which are available to critically ill patients admitted to the current Phase 2/3 FDA trials

Sources with relevant information cited that critically ill COVID-19 patients witnessed a quick recovery from pneumonitis, as displayed by the findings on their x-ray reports. Moreover, an improvement in the patients’ blood oxygen levels were seen alongside a 50% decrease in test center markers related to COVID-19 inflammation.

Prof. Jonathan Javitt, CEO and Chairman of NeuroRx was reported stating that other antiviral agents have failed to show such fast recuperation from a viral disease and exhibited inhibitions towards the multiplication of the virus. He further said that placebo-controlled trials are being carried out by NeuroRx in order to analyze the observations made during open-label and case-control studies.

For those uninitiated, RF-100 is an antiviral agent that has been developed as a Material Threat Medical Countermeasure.

The FDA has reportedly granted Fast Track designation to this antiviral, which is developed through a joint venture agreement among National Institute of Health and numerous other federal agencies, the medicine is being developed as a Material Threat Medical Countermeasure.

 

Source Credits: https://www.prnewswire.com/news-releases/rlf-100-aviptadil-clinical-trial--showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells-301104384.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Bitcoin price spikes to nearly $20,000 with an upsurge in demand
Bitcoin price spikes to nearly $20,000 with an upsurge in demand
By Nikita Chaurasia

Nearly three years after hitting a record price of almost $20,000, the price of bitcoin has again struck the same all-time-high figure. According to a bitcoin price index, CoinDesk, the price of one bitcoin was reportedly recorded to be $19,850.11 on...

Topshops owner Arcadia Group on verge of inevitable collapse
Topshops owner Arcadia Group on verge of inevitable collapse
By Nikita Chaurasia

Arcadia, an expansive retail business comprising of renowned fashion brands such as Topshop, Burton, and Dorothy Perkins, is reportedly on verge of an economic collapse putting about 13,000 jobs at risk. According to credible sources, the future of A...

Microsoft Teams stops working on Internet Explorer 11, effective today
Microsoft Teams stops working on Internet Explorer 11, effective today
By Nikita Chaurasia

Microsoft Teams is undergoing a major change, as the popular web conferencing service is going to stop working on Internet Explorer 11. It has been reported that from November 30, the web-based version of Microsoft Teams will stop working on IE1...

Top Glove shuts down factories amidst rising COVID-19 cases in Malaysia
Top Glove shuts down factories amidst rising COVID-19 cases in Malaysia
By Nikita Chaurasia

  The company has reportedly ceased its operations after 2453 employees tested positive for the Coronavirus. The company’s shares plummeted by 7.5% after the Malaysian government ordered to shut down 28 of its factories. As per relia...

Belcan becomes software engineering services firm Avista’s new owner
Belcan becomes software engineering services firm Avista’s new owner
By Nikita Chaurasia

Belcan, LLC, a leading supplier of engineering, technical recruiting, supply chain, and information technology (IT) services to various sectors, reportedly announced the acquisition of Avista, Inc., a safety-critical and mission-critical software eng...